pentoxifylline has been researched along with Mouth Ulcer in 7 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " Treatment with methotrexate (5 mg/week) and pentoxifylline (300 mg/d) was effective to control oral ulcers, erythema nodosum, and arthritis." | 4.79 | Mouth and genital ulcers with inflamed cartilage (MAGIC syndrome): a case report and literature review. ( Hamai, K; Imai, H; Komatsuda, A; Miura, AB; Mizuki, N; Motegi, M; Ohtani, H, 1997) |
| "Oral mucositis is a frequent side-effect of cancer therapy." | 1.33 | Effects of the tumour necrosis factor-alpha inhibitors pentoxifylline and thalidomide in short-term experimental oral mucositis in hamsters. ( Augusto, RF; Brito, GA; Cunha, FQ; Falcão, BA; Leitão, BT; Lima, V; Rebouças, CG; Ribeiro, RA; Souza, ML, 2005) |
| "Pentoxifylline is a methylxanthine derivative that produces dose-related hemorrheologic effects, lower blood viscosity, improved erythrocyte flexibility, and increased tissue oxygen levels." | 1.30 | Pentoxifylline in the treatment of radiation-related soft tissue injury: preliminary observations. ( Futran, ND; Gwede, C; Trotti, A, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (28.57) | 18.2507 |
| 2000's | 4 (57.14) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Robard, L | 1 |
| Louis, MY | 1 |
| Blanchard, D | 1 |
| Babin, E | 1 |
| Delanian, S | 1 |
| Liang, GC | 1 |
| Chang, EM | 1 |
| Lima, V | 1 |
| Brito, GA | 1 |
| Cunha, FQ | 1 |
| Rebouças, CG | 1 |
| Falcão, BA | 1 |
| Augusto, RF | 1 |
| Souza, ML | 1 |
| Leitão, BT | 1 |
| Ribeiro, RA | 1 |
| Futran, ND | 1 |
| Trotti, A | 1 |
| Gwede, C | 1 |
| Imai, H | 1 |
| Motegi, M | 1 |
| Mizuki, N | 1 |
| Ohtani, H | 1 |
| Komatsuda, A | 1 |
| Hamai, K | 1 |
| Miura, AB | 1 |
| Hongcharu, W | 1 |
| Baldassano, M | 1 |
| Taylor, CR | 1 |
| Oliveira-Soares, R | 1 |
| Freitas, JP | 1 |
| Sousa Ramalho, P | 1 |
| Guerra Rodrigo, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Advances in the Management of Mandibular Osteoradionecrosis: Pentoxifylline and Tocopherol as Medical Treatment[NCT02368457] | Phase 4 | 24 participants (Actual) | Interventional | 2016-02-29 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Clinical healing assessment as measured with the classification of ORN stages, area of bone exposed (mm2) and radiological findings (OPG).~Intraoral bone exposure is measured in mm2." (NCT02368457)
Timeframe: From baseline to 1, 3, 6, and 9 months of starting treatment
| Intervention | mm2 (Mean) | |||
|---|---|---|---|---|
| 1 month of starting treatment | 3 month of starting treatment | 6 month of starting treatment | 9 month of starting treatment | |
| Control Group | 15 | 15 | 15 | 15 |
| Pentoxifylline and Tocopherol | 14 | 13 | 11.5 | 10 |
"Evaluation of symptoms improvement using the LENT-SOMA scale (Late Effect Normal Tissue Task Force / Subjective, Objective, Management, Analytic scale).~To examine the LENT/SOMA scale prospectively using interviews and questionnaires~Assessments were made from baseline to 1, 3, 6 and 9 months of starting treatments. The acceptability and feasibility of using the scales was examined using compliance in completion of the questionnaires.~Maximum score: 36 Minimum score: 0~Questionnaires have been completed for 24 patients after treatment. Higher values represents worse outcome.~Scale categories:~Subjective: pain, nutritional problems, difficulty in mouth openning. Objective: bone exposure, trismus, Management: analgesic treatment, oral treatment, nutrition. Analytic: radiological findings." (NCT02368457)
Timeframe: From baseline to 1,3, 6, 9 months of starting treatment
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| 1 month of starting treatment | 3 month of starting treatment | 6 month of starting treatment | 9 month of starting treatment | |
| CONTROL | 15.5 | 15.5 | 15.5 | 15.5 |
| Pentoxifylline and Tocopherol | 14.5 | 14 | 14 | 13.3 |
1 review available for pentoxifylline and Mouth Ulcer
| Article | Year |
|---|---|
Mouth and genital ulcers with inflamed cartilage (MAGIC syndrome): a case report and literature review.
Topics: Adult; Behcet Syndrome; Drug Therapy, Combination; Female; Genital Diseases, Female; Genotype; HLA A | 1997 |
6 other studies available for pentoxifylline and Mouth Ulcer
| Article | Year |
|---|---|
Medical treatment of osteoradionecrosis of the mandible by PENTOCLO: preliminary results.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Clodronic Acid; Drug Combinations; Female | 2014 |
Pentoxifylline use for Behçet's disease. The result of a survey among rheumatologists in North America.
Topics: Antirheumatic Agents; Behcet Syndrome; Colchicine; Humans; Oral Ulcer; Pentoxifylline; Surveys and Q | 2003 |
Effects of the tumour necrosis factor-alpha inhibitors pentoxifylline and thalidomide in short-term experimental oral mucositis in hamsters.
Topics: Abscess; Animals; Antimetabolites, Antineoplastic; Cricetinae; Disease Models, Animal; Edema; Erythe | 2005 |
Pentoxifylline in the treatment of radiation-related soft tissue injury: preliminary observations.
Topics: Administration, Oral; Aged; Analgesics; Anti-Bacterial Agents; Atrophy; Debridement; Dose-Response R | 1997 |
Kimura's disease with oral ulcers: response to pentoxifylline.
Topics: Administration, Oral; Adult; Angiolymphoid Hyperplasia with Eosinophilia; Humans; Male; Oral Ulcer; | 2000 |
Treatment with pentoxifylline in Behçet's disease.
Topics: Adolescent; Adult; Behcet Syndrome; Dose-Response Relationship, Drug; Drug Administration Schedule; | 2002 |